These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
34. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial). Shah AN, Mentz RJ, Gheorghiade M, Kwasny MJ, Fought AJ, Zannad F, Swedberg K, Maggioni AP, Konstam MA. Am J Cardiol; 2012 Dec 15; 110(12):1803-8. PubMed ID: 22999071 [Abstract] [Full Text] [Related]
35. Prognostic usefulness of anemia and N-terminal pro-brain natriuretic peptide in outpatients with systolic heart failure. Schou M, Gustafsson F, Kistorp CN, Corell P, Kjaer A, Hildebrandt PR. Am J Cardiol; 2007 Nov 15; 100(10):1571-6. PubMed ID: 17996522 [Abstract] [Full Text] [Related]
36. Novel extracellular matrix biomarkers as predictors of adverse outcome in chronic heart failure: association between biglycan and response to statin therapy in the CORONA trial. Ueland T, Aukrust P, Nymo SH, Kjekshus J, McMurray JJ, Wikstrand J, Block D, Zaugg C, Gullestad L. J Card Fail; 2015 Feb 15; 21(2):153-9. PubMed ID: 25451704 [Abstract] [Full Text] [Related]
40. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B, EMPHASIS-HF Investigators. J Am Coll Cardiol; 2013 Oct 22; 62(17):1585-93. PubMed ID: 23810881 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]